A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

• Histologically confirmed EC including: endometrioid, serous, undifferentiated, and carcinomsarcoma
• TP53 WT assessed by NGS via central vendor
• Completed a single line, at least 12 weeks, of platinum-based therapy (not including adjuvant or neoadjuvant tx for Stage 1-II disease) adn achieved confirmed PR or CR by RECIST.
• If Primary Stage IV, may have had surgery or not. If surgery, must have had R0 or R1 resection
• Must be able to initiate study drug 3-8 weeks following completion of final dose of chemo
• ECOG PS 0-1
• No uterine sarcoma
• No concurrent systemic steroid therapy above 10mg prednisone or equivalent
• No previous treatment with an XPO1 inhibitor
• No active brain mets

• Primary
  • PFS
• Secondary
  • OS
  • Safety
  • Time to first subseqent therapy
  • Time to second subsequent therapy
  • PFS2
  • QOL